Skip to main content
DMRA
NASDAQ Life Sciences

Damora Launches First Clinical Trial for DMR-001, a Potential Best-in-Class Blood Cancer Therapy

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$30.02
Mkt Cap
$1.848B
52W Low
$2.45
52W High
$38.325
52W Position info
1125% above low
Off High info
22% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

DMRA has more than doubled off its 52-week low of $2.45.

Summary

Damora has dosed the first patient in its Phase 1/1b CLARITY-101 trial of DMR-001, a long-acting antibody targeting mutant calreticulin in essential thrombocythemia and myelofibrosis. The trial uses an adaptive Bayesian design with a starting dose of 100 mg monthly, aiming to rapidly identify a recommended dose. Preclinical data showed up to 30-fold greater potency and a five-fold longer half-life than a reference antibody, supporting best-in-class potential. This is the company's first clinical program, moving it from preclinical to clinical stage. Initial data are expected in mid-2027, which will be the next major catalyst. The strong cash runway into 2029, noted in the May 10-Q, provides ample funding through these readouts.

At the time of this announcement, DMRA was trading at $30.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.45 to $38.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

DMRA - Latest Insights

DMRA
Nov 04, 2026, 4:06 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $21.60 info
Change: -$1.34 (-6%) info
Market Cap: $1.337B info
DMRA
Nov 04, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $21.60 info
Change: -$1.34 (-6%) info
Market Cap: $1.337B info
DMRA
Aug 10, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $29.54
Real-time Price: $21.60 info
Change: -$7.94 (-27%) info
Market Cap: $1.337B info
DMRA
May 12, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $23.06
Real-time Price: $21.60 info
Change: -$1.46 (-6%) info
Market Cap: $1.337B info
DMRA
May 04, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.98
Real-time Price: $21.60 info
Change: -$4.38 (-17%) info
Market Cap: $1.337B info